Bone marrow derived stem cells for the treatment of end-stage liver disease

Table 1 Prospective studies on bone marrow stem cells therapy in patients with cirrhosis

Ref.	Study design	No. of patients	Disease cause/stage	Cell/harvest	Infusion route/n cell infused
Park et al[69]	Case series	5	Mixed	MNCs (MSCs)	Hepatic artery
Cytotherapy, 2013			CTP B-C	BM aspiration	106-107/kg
Amin et al[64]	Case series	20	HCV	MSCs	Intrasplenic
Clin Transplant, 2013			CTP C	BM aspiration	107
Mohamadnejad et al[57]	Randomized	15	Mixed	MSCs/placebo	Peripheral vein
Liver Int, 2013	Vs untreated control	12 control	CTP A-C	BM aspiration	108
Jang et al[59]	Case series	12	Alcohol	MSCs	Hepatic artery
Liver Int, 2013			CTP A-B	BM aspiration	107
Salama et al[68]	Not-randomized	50	HCV	HSCs	Portal vein/hepatic artery
Stem Cell Res Ther, 2012	Vs untreated control	50 control	ESLD	Leukapheresis
				G-CSF	109
El-Ansary et al[65]	Not-randomized	15	HCV	MSCs	Peripheral vein
Stem Cell Rev, 2012	Vs untreated control	10 control	CTP C	BM aspiration	106
Peng et al[61]	Not-randomized	53	HBV	MSCs	Hepatic artery
Hepatology, 2011	Vs untreated control	105 control	Mixed1	BM aspiration	NA
Couto et al[53]	Case series	8	Mixed	MNCs	Hepatic artery
Liver Int, 2010			CTP B-C	BM aspiration	109
Nikeghbalian et al[58]	Case series	6	Mixed	MNCs/HSCs	Portalvein
Arch Iran Med, 2011			CTP C	BM aspiration	106-109
Salama et al[66]	Randomized	90	HCV	HSCs	Portal vein
World J Gastroenterol, 2010	Vs untreated control	50 control	NA	BM aspiration	107
				G-CSF
Kim et al[56]	Case series	10	HBV	MNCs	Peripheral vein
Cell Transplantation, 2010			MELD 7-13	BM aspiration	108/kg
Lyra et al[62]	Randomized	15	Mixed	MNCs	Hepatic artery
Eur J Gastroenterol Hepatol, 2009	Vs untreated control	15 control	CTP B-C	BM aspiration	108
Kharaziha et al[67]	Case series	8	Mixed	MSCs	Portal vein
Eur J Gastroenterol Hepatol, 2009			MELD > 10	BM aspiration	108
Pai et al[63]	Case series	9	alcohol	HSCs	Hepatic artery
AM J Gastroenterol, 2008			CTP B	Leukapheresis	108
				G-CSF
Levicar et al[54]	Case series	5	Mixed	HSCs	Portalvein/
Cell Proliferat, 2008			CTP A-B	Leukapheresis	hepaticartery
				G-CSF	108
Mohamadnejad et al[55]	Case series	4	Mixed	HSCs	Hepatic artery
World J Gastroenterol, 2007			CTP B-C	BM aspiration	106-107
Lyra et al[70]	Case series	10	Mixed	MNCs	Hepatic artery
World J Gastroenterol, 2007			CTP B-C	BM aspiration	108
Terai et al[44]	Case series	9	Mixed	MNCs	Peripheral vein
Stem cells, 2006			CTP B-C	BM aspiration	109

¹In this study the patients had cirrhosis or chronic hepatitis. BMSC: Bone marrow stem cell; CTP :Child Turcotte Pugh score; MNC: Mononuclear stem cell; HSC: Hematopoietic stem cell; MSC: Mesenchymal stem cells; NA: Not available; GI: Gastrointestinal; Pt: Patients.

Table 2 Studies that reported a modification of laboratory parameters and prognostic scores

Author	Results compared to	Laboratory parameters				Prognostic scores
		INR	TBil	Alb	Cr	MELD	CTP
Amin et al[64]	Baseline	I	I	I	NR	NR	NR
Mohamadnejad et al[57]	Control group	NI	NR	NI	NR	NI	NI
Jang et al[59]	Baseline	I	NI	I	NI	I	I
Salama et al[68]	Baseline	NR	I	NR	NR	NR	NR
El-Ansary et al[65]	Control group	I1	I	I	NR	I	NR
Peng et al[61]	Control group	I	I	I	NR	I	NR
Couto et al[53]	Baseline	NR	I	I	NR	NR	NR
Salama et al[66]	Control group	NR	I	I	NR	NR	NR
Kim et al[56]	Baseline	I	NR	I	NR	NI	I
Lyra et al[62]	Baseline	NR	NR	I	NR	NI	I
Kharaziha et al[67]	Baseline	I	NI	NI	I	I	NR
Pai et al[63]	Baseline	NR	I	NI	NR	NR	NR
Terai et al[44]	Baseline	NR	NR	I	NR	NR	I

¹In this study it was reported prothrombin concentration (PC) and not INR. I: Improved significantly; NI: Not improved; NR: Not reported; INR: International normalized ratio; MELD: Model for end-stage liver disease; CTP: Child turcotte pugh score.